Why the study?
Does chronic low-dose aspirin treatment result in different COX-1 sensitivity and thromboxane A2 production in diabetic patients compared to high-risk non-diabetic subjects?
Does chronic low-dose aspirin treatment result in different COX-1 sensitivity and thromboxane A2 production in diabetic patients compared to high-risk non-diabetic subjects?
Diabetic patients on chronic low-dose aspirin have reduced platelet sensitivity to aspirin compared to non-diabetics, which appears to be driven by hyperglycemia.
No takes yet. Share an insight, caveat, or question.
May indicate reduced aspirin sensitivity in diabetes; hypothesis-generating and should not yet change practice.
Pulcinelli et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: